Respiratory Medicine
Volume 104, Issue 11 , Pages 1659-1667 , November 2010

COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT)

  • A.H. Morice

      Affiliations

    • Cardiovascular and Respiratory Studies, HullYork Medicine School, University of Hull, CastleHill Hospital, Castle Road, Cottingham, East Yorkshire, HU16 5JQ, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1482 622308/624067; fax: +44 1482 624068.
    • ,
  • B. Celli

      Affiliations

    • Brigham and Women’s Hospital, Boston, MA, USA
    • ,
  • S. Kesten

      Affiliations

    • Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
    • ,
  • T. Lystig

      Affiliations

    • Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
    • ,
  • D. Tashkin

      Affiliations

    • David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    • ,
  • M. Decramer

      Affiliations

    • University of Leuven, Leuven, Belgium

Received 13 April 2010 ,Accepted 26 July 2010.

References 

  1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765–773
  2. de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004;59:120–125
  3. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997;10:815–821
  4. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–224
  5. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456
  6. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81
  7. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332–338
  8. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:948–955
  9. Kerstjens HA, Brand PL, Postma DS. Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:S266–S272
  10. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171–1178
  11. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554
  12. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63:402–407
  13. Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology. 2003;8:504–508
  14. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest. 2004;125:1394–1399
  15. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31:1334–1356
  16. Bathoorn E, Kerstjens H, Postma D, Timens W, MacNee W. Airways inflammation and treatment during acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:217–229
  17. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–459
  18. Mannino DM. Women and chronic obstructive pulmonary disease: does sex influence survival?. Am J Respir Crit Care Med. 2006;174:488–489
  19. Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med. 2006;173:985–990
  20. Furberg H, Sullivan PF, Maes H, Prescott CA, Lerman C, Bulik C, et al. The types of regular cigarette smokers: a latent class analysis. Nicotine Tob Res. 2005;7:351–360
  21. Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J. 2009;
  22. de Marco R, Accordini S, Anto JM, Gislason T, Heinrich J, Janson C, et al. Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. Am J Respir Crit Care Med. 2009;180:956–963

PII: S0954-6111(10)00337-9

doi: 10.1016/j.rmed.2010.07.016

Respiratory Medicine
Volume 104, Issue 11 , Pages 1659-1667 , November 2010

Article Tools

* Image Usage & Resolution